NCT05640895Completed
Intravitreal Injection Site and Perceived Pain
The Effect of Entry Site Distance From Limbus on Perceived Pain During Intravitreal Injection of Anti-VEGF (Vascular Endothelial Growth Factor) Agents
Source: ClinicalTrials.gov · Last updated 31 Jan 2025
Brief summary (registry, in English)
The objective of this study is to explore the perception of pain during intravitreal injection related to the distance of the entry site from the limbus.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 53 (actual)
- First submitted
- 28 Nov 2022
- Start date
- 14 Nov 2022
- Primary completion date
- 18 Dec 2023
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Diseases
- Macular degeneration, Diabetic eye disease
- NCT number
- NCT05640895
What you commit to
- Study type: Observational
- Participants enrolled: 53
- From 14 Nov 2022 to the primary completion date, 18 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Under 18 years-of-age
Other
- Texas Department of Corrections medical records
- First intravitreal injection experience of patient
Who the study is looking for
- Age 18 -100 years
- Diagnosis of diabetic macular edema, age related macular degeneration, or retinal vein occlusion
- Treated with bevacizumab, ranibizumab, aflibercept
- The need for at least two intravitreal injections
- Pseudophakia
Age in the registry: 18 years to 100 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Texas Medical Branch Coordinator of this site? Confirm its status | Galveston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.